From: Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea
Year | 2005 | 2006 | 2007 | 2008 | 2009 | |||||
---|---|---|---|---|---|---|---|---|---|---|
Statins | Original | Generic** | Original | Generic** | Original | Generic** | Original | Generic** | Original | Generic** |
Simvastatin (10, 20, 40, 80Â mg) | 3 | 125 | 3 | 134 | 3 | 135 | 3 | 118 | 4 | 100 |
Lovastatin (20Â mg) | 1 | 54 | 1 | 56 | 1 | 52 | 1 | 35 | 1 | 25 |
Pravastatin (5,10,20,40Â mg) | 0 | 49 | 0 | 50 | 0 | 81 | 0 | 56 | 0 | 48 |
Fluvastatin (20,40,80Â mg) | 3 | 0 | 3 | 0 | 3 | 0 | 3 | 0 | 3 | 0 |
Atorvastatin (10,20,40,80Â mg) | 3 | 0 | 3 | 0 | 3 | 0 | 4 | 42 | 4 | 54 |
Rosuvastatin (5,10,20Â mg) | 2 | 0 | 3 | 0 | 3 | 0 | 3 | 0 | 3 | 0 |
Pitavastatin (2Â mg) | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 |
Total | 241 | 254 | 282 | 266 | 243 |